CD79B Antibody (G-7): sc-166675

CD79B Antibody (G-7) is a mouse monoclonal IgG2a antibody that detects CD79B in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD79B, also known as B29, plays a crucial role in the formation of the B cell antigen receptor complex by pairing with CD79A, which is essential for B cell activation and signaling. Anti-CD79B antibody (G-7) facilitates the study of surface expression of membrane immunoglobulins, such as IgM and IgD, which are vital for effective antigen recognition and immune response. Additionally, the cytoplasmic tail of CD79B contains an immuno-receptor tyrosine-based activation motif (ITAM) that is critical for initiating downstream signaling pathways upon antigen binding, ultimately leading to B cell proliferation and differentiation. CD79B monoclonal antibody (G-7) is an invaluable tool for researchers studying B cell biology and the mechanisms underlying immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79B Antibody (G-7) References:

1. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis.  |  Cragg, MS., et al. 2002. Blood. 100: 3068-76. PMID: 12384401
2. Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line.  |  Minuzzo, S., et al. 2005. Br J Haematol. 130: 878-89. PMID: 16156858
3. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.  |  O'Neill, SK., et al. 2011. Immunity. 35: 746-56. PMID: 22078222
4. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.  |  Saieg, MA., et al. 2013. Cancer Cytopathol. 121: 377-86. PMID: 23361872
5. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.  |  Kraan, W., et al. 2014. Leukemia. 28: 719-20. PMID: 24253023
6. Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.  |  Jovanovic, D., et al. 2014. Contemp Oncol (Pozn). 18: 29-33. PMID: 24876818
7. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.  |  Kersten, MJ., et al. 2014. Blood Cancer J. 4: e266. PMID: 25501023
8. Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.  |  Santos, Gda C., et al. 2015. Cancer Cytopathol. 123: 413-20. PMID: 25807917
9. Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5+ diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report.  |  Chen, X., et al. 2024. Transl Cancer Res. 13: 1188-1195. PMID: 38482415
10. High Prevalence of MYD88 and CD79B Mutations in Primary Sinonasal Diffuse Large B-Cell Lymphoma: Identification of an MCD-like Subtype.  |  Peng, F., et al. 2025. Am J Surg Pathol. 49: 159-168. PMID: 39483112

The preferred CD79B antibody is CD79B Antibody (B29/123): sc-53210.